EDMONTON, Alberta--BioTools and Varian have agreed to develop a new magnetic resonance diagnostic tool over the course of an expected three-year project. The effort will involve the clinical application of nuclear magnetic resonance spectroscopy and advanced computational tools such as pattern recognition to the diagnosis and monitoring of disease and health. It also has potential applications in drug and toxicity testing.
The goal of the project is to provide clinicians with an alternative to existing diagnostic instruments that is capable also of recording and interpreting complex biochemical profiles found in biological fluids.
Using pattern recognition methods and specialized databases specific to individual disease states, this application of MRD technology should reveal large amounts of information in a single test sample, ultimately enabling clinicians to more accurately diagnose disease states such as renal disease and cancer, among others.